Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.

Journal for immunotherapy of cancer - 2 Feb 2024

Esposito Abate Riziero, Pasquale Raffaella, Sacco Alessandra, Simeon Vittorio, Maiello Monica Rosaria, Frezzetti Daniela, Chiodini Paolo, Normanno Nicola

Abstract excerpt

BACKGROUND: Although conflicting results emerged from different studies, the tumor mutational burden (TMB) appears as one of most reliable biomarkers of sensitivity to immune checkpoint inhibitors. Several laboratories are reporting TMB values when performing comprehensive genomic profiling (CGP) without providing a clinical interpretation, due to the lack of validated cut-off values. The International Quality...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 38309725
DOI: 10.1136/jitc-2023-007800
PMCID: PMC10840060

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.PMID 38309725Read ↗

Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels.Semantic proximity Read ↗

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB.Semantic proximity Read ↗

Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path).Semantic proximity Read ↗

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.Semantic proximity Read ↗

Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.Semantic proximity Read ↗

External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme.Semantic proximity Read ↗

Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small Cell Lung CancerSemantic proximity Read ↗

Designing gene panels for tumor mutational burden estimation: the need to shift from ‘correlation’ to ‘accuracy’Semantic proximity Read ↗

Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.Semantic proximity Read ↗

Expert consensus on the detection and clinical application of tumor mutational burden.Semantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker in Solid TumorsSemantic proximity Read ↗

Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.